Health AI Central
Share:
Peer-Reviewed Publication
Ther Adv Gastroenterol2026;1917562848261462398.January 1, 2026Journal Article

Using artificial intelligence to identify characteristics associated with clinical and economic outcomes in MASH (FOCUS-MASH).

Kamal Kant Mangla1, Semiu O Gbadamosi2, Daniel Semeniuta3, Jigar Bandaria3, Joseph Zabinski3, Gary Curhan3, Costas Boussios3
1Novo Nordisk Service Centre India Pvt. Ltd., Bengaluru, KA 560066, India.
2Novo Nordisk Inc., Plainsboro, NJ, USA.
3OM1, Inc., Boston, MA, USA.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Heterogeneity in the disease characteristics of metabolic dysfunction-associated steatohepatitis (MASH) complicates efforts to identify individuals with high unmet need. OBJECTIVE: We used artificial intelligence (AI) phenotyping to identify factors associated with rapid fibrosis progression, long-term clinical outcomes, and high healthcare costs. DESIGN: In this retrospective cohort…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.